Clinical TrialApr 28, 2026, 09:16 AM
NXL Study Shows Significant Sleep Quality Improvement in Insomnia
AI Summary
Nexalin Technology announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics, reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia. The study found that patients treated with Nexalin's 15 mA, 77.5 Hz Deep Intracranial Frequency Stimulation (DIFS™) experienced a statistically significant reduction in Pittsburgh Sleep Quality Index (PSQI) scores from 13.8 to 7.7, while the sham group showed no significant change. This publication provides mechanistic support for Nexalin's proprietary DIFS™ technology and further validates its non-pharmacologic treatment strategy for mental health issues.
Key Highlights
- Peer-reviewed study published in Psychotherapy and Psychosomatics.
- Active treatment group PSQI scores reduced from 13.8 to 7.7 (p < 0.001).
- Sham group PSQI scores showed no significant change (13.8 to 13.9, p = 0.74).
- Study used Nexalin's 15 mA, 77.5 Hz Deep Intracranial Frequency Stimulation (DIFS™).
- Neuroimaging data showed modulation of Default and Salience/Ventral Attention networks.
- Findings provide mechanistic support for Nexalin's proprietary DIFS™ technology.
- Adds to clinical literature, including HALO™ Clarity pivotal program for FDA submission.
- Nexalin's Gen-2 15 mA device approved in China, Brazil, Oman, and Israel.
Price Impact
More from NXL